ALT Altimmune Inc.

1.91
-0.1  -5%
Previous Close 2.01
Open 1.98
Price To Book 0.59
Market Cap 29,295,718
Shares 15,338,072
Volume 347,877
Short Ratio
Av. Daily Volume 222,896
Stock charts supplied by TradingView

NewsSee all news

  1. Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer

    Preclinical study shows systemic activity of ALT-702 following local administration Altimmune granted U.S. patent providing broad coverage of platform technology GAITHERSBURG, Md., Jan. 23, 2020 (GLOBE NEWSWIRE) --

  2. Altimmune to Present at the 2020 NASH-TAG Conference

    GAITHERSBURG, Md., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced an oral presentation at the 2020 NASH-TAG Conference being held on January

  3. Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH

    GAITHERSBURG, Md., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on ALT-801, the Company's

  4. Altimmune Announces Third Quarter 2019 Financial Results and Provides a Business Update

    GAITHERSBURG, Md., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended September 30, 2019 and provided a

  5. Altimmune to Announce Third Quarter 2019 Financial Results on November 14

    GAITHERSBURG, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies, today announced that it

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial planned for 2020.
HepTCell
Hepatitis B
Phase 2 additional data released March 19, 2019 noted all patients remained seroprotected.
NasoVAX
Flu vaccine
Phase 1b trial to be initiated in 1Q 2020.
NASOSHIELD
Anthrax
IND to be filed in 2020 with Phase 1 data due 2021.
ALT-801
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer

    Preclinical study shows systemic activity of ALT-702 following local administration Altimmune granted U.S. patent providing broad coverage of platform technology GAITHERSBURG, Md., Jan. 23, 2020 (GLOBE NEWSWIRE) --

  2. Altimmune to Present at the 2020 NASH-TAG Conference

    GAITHERSBURG, Md., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced an oral presentation at the 2020 NASH-TAG Conference being held on January

  3. Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH

    GAITHERSBURG, Md., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on ALT-801, the Company's

  4. Altimmune Announces Third Quarter 2019 Financial Results and Provides a Business Update

    GAITHERSBURG, Md., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended September 30, 2019 and provided a

  5. Altimmune to Announce Third Quarter 2019 Financial Results on November 14

    GAITHERSBURG, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies, today announced that it

  6. Altimmune to Participate in Upcoming Investor Conferences

    GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that management will participate in the following investor conferences

  7. Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer

    GAITHERSBURG, Md., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced it has appointed M. Scott Harris, M.D. as Chief Medical Officer. Dr.